Acne Vulgaris Pipeline Analysis Report 2025

Acne vulgaris is a chronic inflammatory skin disease affecting the hair follicles and sebaceous glands, commonly seen in adolescents. The need for advanced therapies is driving innovation, with a growing focus on non-antibiotic and hormone-based treatments. Recent developments include topical retinoids, androgen receptor inhibitors, and immunomodulators. Acne vulgaris pipeline analysis by the publisher highlights promising candidates like clascoterone, trifarotene, and sarecycline that are undergoing clinical development. With rising skin care awareness, improved formulations, and expanding clinical trials, the acne vulgaris therapeutics market is poised for strong growth in the coming years.

Report Coverage

The Acne Vulgaris Pipeline Analysis Report by the publisher gives comprehensive insights into acne vulgaris therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for acne vulgaris. The acne vulgaris report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The acne vulgaris pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with acne vulgaris treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical study, phase type, drug type, route of administration, and ongoing product development activities related to acne vulgaris.

Acne Vulgaris Pipeline Outlook

Acne vulgaris is a common chronic skin condition that occurs when hair follicles become clogged with oil and dead skin cells. It often leads to whiteheads, blackheads, pimples, or cysts, primarily on the face, chest, and back. Hormonal changes, excess sebum production, bacterial growth, and inflammation contribute to its development, particularly during adolescence.

Acne vulgaris treatment includes topical or oral antibiotics, retinoids, benzoyl peroxide, and hormonal therapies to reduce inflammation, clear pores, and prevent new breakouts. For instance, in October 2023, the U.S. Food and Drug Administration approved CABTREO, a fixed-dose triple-combination topical gel for acne vulgaris, offering once-daily treatment with proven efficacy and simplified dosing.

Acne Vulgaris Epidemiology

Acne vulgaris has a global prevalence of 20.5%, affecting 1 in 5 individuals. Epidemiological data show the highest incidence in adolescents and young adults at 28.3%, followed by adults aged 25 to 39 at 19.3%. Women are affected more at 23.6% compared to men at 17.5%. Regional prevalence is highest in Latin America at 23.9% and East Asia at 20.2%, highlighting the need for targeted dermatological interventions.

Acne Vulgaris - Pipeline Therapeutic Assessment

This section of the report covers the analysis of acne vulgaris drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Biologics
• Hormonal Agents
• RNA-Based Therapies
• Nanoparticle/Formulation-based Molecules
• Others

By Route of Administration

• Oral
• Parenteral
• Others

Acne Vulgaris Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III accounts for 39.22% of the acne vulgaris drug pipeline, highlighting significant late-stage clinical activity. Phase II follows with 31.37%, indicating a strong mid-stage pipeline. Phase IV represents 11.76%, showing continued post-marketing research. Phase I covers 11.76%, and Early Phase I holds 5.88%. This balanced progression supports future innovation and market growth in the acne vulgaris treatment landscape.

Acne Vulgaris Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the acne vulgaris pipeline analysis include small molecules, biologics, hormonal agents, RNA-based therapies, nanoparticle/formulation-based molecules, and others. The acne vulgaris report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for acne vulgaris.

Vaccine-based immunotherapies are emerging as novel drug classes in the acne vulgaris treatment pipeline. For example, Sanofi’s acquisition of Origimm Biotechnology introduced ORI-001, a recombinant protein-based therapeutic vaccine candidate. It targets Cutibacterium acne and aims to modulate the immune response. Sanofi also plans to utilize its mRNA platform to advance the candidate into early-phase clinical trials.

Acne Vulgaris Clinical Trials - Key Players

The report for the acne vulgaris pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed acne vulgaris therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in acne vulgaris clinical trials:

• Dermata Therapeutics
• Pfizer
• Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
• Eurofarma Laboratorios S.A.
• Biofrontera Bioscience GmbH
• Sun Pharmaceutical Industries Limited
• Ascletis Pharmaceuticals Co., Ltd.
• Sanofi Pasteur
• Maruho Co., Ltd.
• Allergan
• Novartis Pharmaceuticals
• Incyte Corporation

Acne Vulgaris - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for acne vulgaris. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of acne vulgaris drug candidates.

Drug: DMT310

DMT310-009, sponsored by Dermata Therapeutics, is currently undergoing a Phase III clinical trial to evaluate its tolerability, safety, and efficacy in patients with moderate to severe acne vulgaris. DMT310 (branded as XYNGARI) is a once-weekly topical treatment derived from a freshwater sponge, utilizing mechanical exfoliation and bioactive compounds with antimicrobial and anti-inflammatory properties.

Drug: ASC40

ASC40, developed by Ascletis Pharmaceuticals Co., Ltd., is being evaluated in a Phase III extension trial to assess its long-term safety in patients with moderate to severe acne vulgaris. The study is enrolling patients from a prior trial and is administering ASC40 (Denifanstat), a selective oral FASN inhibitor. It targets reduced sebum production and inflammation.

Reasons To Buy This Report

The Acne Vulgaris Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for acne vulgaris. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within acne vulgaris pipeline insights.

Key Questions Answered in the Acne Vulgaris Pipeline Insight Report

• Which companies/institutions are leading the acne vulgaris drug development?
• What is the efficacy and safety profile of acne vulgaris pipeline drugs?
• Which company is leading the acne vulgaris pipeline development activities?
• What is the current acne vulgaris commercial assessment?
• What are the opportunities and challenges present in the acne vulgaris pipeline landscape?
• What is the efficacy and safety profile of acne vulgaris pipeline drugs?
• Which company is conducting major trials for acne vulgaris drugs?
• Which companies/institutions are involved in acne vulgaris collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in acne vulgaris?

This product will be delivered within 3-5 business days.